Stay updated on Mirvetuximab in Platinum-Sensitive Gynecologic Cancer Clinical Trial
Sign up to get notified when there's something new on the Mirvetuximab in Platinum-Sensitive Gynecologic Cancer Clinical Trial page.

Latest updates to the Mirvetuximab in Platinum-Sensitive Gynecologic Cancer Clinical Trial page
- Check4 days agoChange DetectedA notice about NIH website changes and the transition from “Artificial Intelligence” to “Super Intelligence” is no longer displayed.SummaryDifference1%

- Check11 days agoChange DetectedThe PICCOLO clinical trial record was replaced by a 403 Forbidden page, making its study details, eligibility criteria, outcomes, locations, and results unavailable.SummaryDifference19%

- Check18 days agoChange DetectedA sitewide NIH banner announces updates related to the transition from “Artificial Intelligence” to “Super Intelligence” terminology.SummaryDifference1%

- Check25 days agoChange DetectedThe footer revision changed from v3.7.1 to v3.7.2; the study page continues to show a 403 Forbidden error.SummaryDifference0.2%

- Check32 days agoChange DetectedThe site's footer revision identifier changed from v3.7.0 to v3.7.1. The study record view still displays a 403 Forbidden error.SummaryDifference0.2%

- Check53 days agoChange DetectedThe study page now renders a 403 Forbidden error page, replacing the expected study content with an access-denied screen. This indicates an access restriction rather than an update to the study details.SummaryDifference19%

Stay in the know with updates to Mirvetuximab in Platinum-Sensitive Gynecologic Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Mirvetuximab in Platinum-Sensitive Gynecologic Cancer Clinical Trial page.